Search Results for “EU” – Page 372 – media

Google-Backed FLX Bio Scores $60M Financing

FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small-molecule drugs to activate the immune system against cancer, today announced the completion of a $60 million Series C private financing. The financing included new investments from GV (formerly Google Ventures) and other undisclosed investors as well as existing investors including The Column Group, Kleiner Perkins, Topspin Partners and Celgene Corporation.
- Source: Flxbio
- 422
- December 27, 2017
Market Views oral small-molecule drugs
AZ and ICL link to research respiratory diseases

AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
- Source: pharmatimes
- 549
- December 27, 2017
asthma AstraZeneca COPD Market Views
High Performance Computing and Big Data in Medicine and Pathology

Innovative data processing technologies allow for new form of medicine, called Personalized or Precision Medicine (PerMed), which is using information about a person’s genes, proteins, and environment to prevent, diagnose and treat diseases. Each type of cancer has its own genetic makeup, giving each tumor cell and tissue a unique character with specific tendencies and vulnerabilities.
- Source: europa
- 658
- December 26, 2017
PerMed Researches
Self-Powered Paper Patch Help Diabetics Measure Glucose During Exercise

A new paper-based sensor patch developed by researchers at Binghamton University, State University of New York could allow diabetics to effectively measure glucose levels during exercise.
- Source: mindsofmalady
- 498
- December 26, 2017
blood glucose levels Researches sensor
Janssen buys into Legend’s CART therapy

Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy LCAR-B38M.
- Source: Pharmatimes
- 412
- December 26, 2017
CAR-T therapy Company Insight Market Views
Roche and Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche.
- Source: Roche
- 529
- December 25, 2017
Ignyta Market Views Roche
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. (Janssen) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC). Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.
- Source: Janssen
- 489
- December 25, 2017
CRPC inhibitor New Approvals
Sensor-enhanced surgical robot enables highly precise and safe spinal operations

Researchers from the University of Bern, Inselspital, Bern University Hospital and the Swiss Center for Electronics and Microtechnology develop a high-precision, sensor-based surgical robot for spinal operations together with industry partners. Their project is being funded with two million Swiss francs, sponsored by the "BRIDGE" programme of the Swiss National Science Foundation and the Commission for Technology and Innovation.
- Source: medicalxpress
- 379
- December 22, 2017
Researches robotic surgery spinal
What Happens When You Get Pregnant In Your 20s, 30s, 40s

There's no shortage of info (and misinformation) out there about when to get pregnant - or when not to. But no matter what your search engine, great aunt, or the random lady standing next to you in line for coffee says, there's no magical right time. However, there are plenty of factors that may offer a sneak peek into the type of pregnancy you'll have. How old you are? Yep, that's definitely one of them.
- Source: msn
- 424
- December 22, 2017
pregnant Researches
AbbVie Scores Key Trial Win for RA Drug With One Fatal Event Reported

AbbVie’s investigational JAK1-inhibitor upadacitinib yielded positive top-line results in a Phase III trial as a monotherapy for rheumatoid arthritis patients. But the drug shows that it is still plagued by some safety concerns.
- Source: Biospace
- 577
- December 21, 2017
Clinical Trials inhibitor Phase rheumatoid arthritis

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.